AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Headlines:
- Completion of Initial Study: Tryptamine Therapeutics (ASX:TYP) has finalized its first intravenous (IV) psilocin injection study with 11 patients, focusing on establishing baseline safety data.
- Safety and Dosage Focus: The study, involving a two-and-a-half-hour IV infusion, aimed to determine the optimal dosage and infusion rate for future trials, with all participants discharged without incident.
- Positive Previous Results: The company also reported a successful oral psilocybin trial, noting a significant reduction in binge eating episodes, and is preparing for additional clinical trials based on the safety data from this phase.
Tryptamine Therapeutics (ASX:TYP) has completed its first-ever intravenous (IV) psilocin injections as part of a Phase 1b study involving 11 participants. This study aimed to establish baseline safety data for further investigations into the drug's effects.
During the study, participants received psilocin via IV over a period of two and a half hours. All individuals were discharged without any incidents. The primary goal of this phase was not to evaluate the drug’s outcomes but to gather safety data and determine optimal infusion rates for future trials.
The company is focused on identifying the ideal infusion rate to minimize risks and enhance the efficacy of subsequent studies. The ongoing safety review will help refine the therapeutic dose and ensure consistent blood concentrations of psilocin during treatment.
Tryptamine Therapeutics has also reported successful outcomes from an earlier oral psilocybin trial, where patients with binge eating disorders experienced an over 80% reduction in episodes. The results from the IV psilocin study are expected to support the development of future clinical trials and collaborations with regulatory bodies.
This update marks a significant step for Tryptamine Therapeutics as it advances its research into psychedelic therapies aimed at treating mental health conditions. The company's progress aligns with the broader trend of healthcare juniors exploring innovative treatments.
